Key points are not available for this paper at this time.
Better targeting of antimalarials to people who need them will maximize the impact of interventions in the private sector.
Cohen et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: